BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027
Five years after their pandemic-era success, BioNTech and Moderna are racing to transform promising medical breakthroughs into sustainable businesses.
Biotechnology firms BioNTech and Moderna, giants of COVID-19 vaccine production, are navigating a new era as the pandemic wanes. Investors are left to ponder which company can harness its scientific advancements into enduring growth, and diminish reliance on shrinking vaccine revenues. While both possess significant potential, their fiscal health, clinical advancements, and profitability trajectories suggest vastly different futures by 2027.
BioNTech, a pioneer in messenger RNA (mRNA) technology, is diversifying its portfolio into cancer treatments and vaccines. This shift was evident in FY 2025, when revenue grew to nearly $3.2 billion, a modest 4.3% increase year-over-year. However, the company reported a significant net loss of nearly $1.3 billion, resulting in a net margin of roughly -39.6%.
This loss is largely attributed to capital being funneled into its expansive oncology pipeline. BioNTech's advantage lies in its substantial cash reserves, totaling approximately €16.2 billion as of September 2026, providing ample funding for clinical trials and new therapeutic avenues without excessive reliance on external financing.
Moderna, which also develops medicines for infectious diseases, cancer, and rare genetic disorders using mRNA technology akin to BioNTech, reported a more challenging 2025, with revenue of around $1.9 billion—marking a 40% year-over-year decline. The company suffered a net loss of $2.8 billion, as vaccine sales weakened and research expenditures remained high.
Yet, recent data hints at a turnaround; Moderna's revenue surged 29% to $1.3 billion in the third quarter of 2026, and net income reached $162 million. The company is projecting a revenue growth outlook of 15%-25% for the full year, though COVID-19 vaccines continue to be its main revenue driver. Moderna's cash reserves as of September 2026 stood at $8 billion, bolstered by new convertible debt, yet high research spending remains a concern.
The primary risk for BioNTech is the progress of its oncology pipeline, where clinical failures or regulatory hurdles could delay new revenue streams. Additionally, competition in cancer treatments and ongoing vaccine sales declines could prolong its period of operating losses. Moderna faces analogous clinical risks, compounded by financial pressure from dwindling vaccine revenue and persistent cash burn.
Established pharmaceutical companies such as Pfizer, Sanofi, and GSK pose heightened competition, while patent disputes and evolving vaccine guidelines introduce further unpredictability.
When comparing the two, BioNTech seems the more financially robust option, thanks to its positive cash flow and lack of debt. Moderna, on the other hand, is grappling with significant revenue declines and negative cash generation. Valuing these companies proves challenging due to their ongoing losses and uncertain future drug approvals.
Traditional earnings multiples offer little insight, making it more useful to assess their revenue valuations and financial strength. For investors looking ahead to 2027, BioNTech emerges as the preferred investment, with Moderna's potential cancer vaccine promising a lucrative commercial opportunity, though its high valuation and ongoing cash needs warrant caution.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
